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Association between acute
kidney injury and long-term
mortality in patients with
aneurysmal subarachnoid
hemorrhage: A retrospective
study
Yangchun Xiao1† , Jun Wan2† , Yu Zhang1,3 , Xing Wang3 ,
Hanwen Zhou4 , Han Lai5 , Weelic Chong6 , Yang Hai7 ,
L. Dade Lunsford8 , Chao You3 , Shui Yu9* and Fang Fang3*
1
Department of Neurosurgery, Affiliated Hospital of Chengdu University, Chengdu, China, 2 Key
Laboratory of Pattern Recognition and Intelligent Information Processing, Institutions of Higher
Education of Sichuan Province, Chengdu University, Chengdu, China, 3 Department of
Neurosurgery, West China Hospital, Sichuan University, Chengdu, China, 4 West China School of
Public Health, Sichuan University, Chengdu, China, 5 Department of Nephrology, The First Affiliated
Hospital of Chongqing Medical University, Chongqing, China, 6 Department of Medical Oncology,
Thomas Jefferson University, Philadelphia, PA, United States, 7 Department of Radiology, Thomas
Jefferson University, Philadelphia, PA, United States, 8 Department of Neurosurgery, University of
Pittsburgh Medical Center, Pittsburgh, PA, United States, 9 Department of Neurosurgery, Dujiangyan
People’s Hospital, Dujiangyan, China

Background: Though acute kidney injury (AKI) in the context of aneurysmal
subarachnoid hemorrhage (aSAH) worsens short-term outcomes, its impact
on long-term survival is unknown.
Aim: We aimed to evaluate the association between long-term mortality and
AKI during hospitalization for aSAH.
Methods: This was a retrospective study of patients who survived >12
months after aSAH. All patients were evaluated at West China Hospital, Sichuan
University, between December 2013 and June 2019. The minimum follow-up
time was over 1 year. the maximum follow-up time was about 7.3 years. AKI
was deﬁned by the KDIGO (The Kidney Disease Improving Global Outcomes)
guidelines, which stratiﬁes patients into three stages of severity. The primary
outcome was long-term mortality, which was analyzed with Kaplan-Meier
curves and Cox proportional hazards models.
Results: During this study period, 238 (9.2%) patients had AKI among 2,592
patients with aSAH. We conﬁrmed that AKI during care for aSAH signiﬁcantly
increased long-term mortality (median 4.3 years of follow-up) and that risk
increased with the severity of the kidney failure, with an adjusted hazard ratio
(HR) of 2.08 (95% CI 1.49–2.89) for stage 1 AKI, 2.15 (95% CI 1.05–4.43) for
stage 2 AKI, and 2.66 (95% CI 1.08–6.53) for stage 3 AKI compared with patients
without AKI. Among patients with an AKI episode, those with renal recovery still
had increased long-term mortality (HR 1.96; 95% CI 1.40–2.74) compared with
patients without AKI but had better long-term outcomes than those without
renal recovery (HR 0.51, 95% CI 0.27–0.97).
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Conclusions:
Among 12-month survivors of aSAH, AKI during their
initial hospitalization for aSAH was associated with increased long-term
mortality, even for patients who had normal renal function at the time of
hospital discharge. Longer, multidisciplinary post-discharge follow-up may be
warranted for these patients.
KEYWORDS

intracranial aneurysm, subarachnoid hemorrhage, mortality, acute kidney injury,
prognostic factors, complication

Introduction

Methods
Study design

Aneurysmal subarachnoid hemorrhage (aSAH) is a serious
disease with high case fatality. Regarding short-term mortality,
a meta-analysis of 33 studies found a case fatality from
8.3 to 66.7% and has decreased by 17% during the past
three decades (1). This improvement in short-term survival
underscores the need to consider the long-term outcomes.
Patients who are alive 12 months after aSAH still face a 1.5-fold
higher long-term mortality than the general population, mostly
related to cardiovascular and cerebrovascular disease (2, 3).
Moreover, the long-term effects of certain complications during
hospitalization for aSAH are still unclear, leading to questions
about best clinical practices and allocation of healthcare
resources (2, 4).
Acute kidney injury (AKI) is a complication that has been
reported as occurring in ∼20% of patients who suffer strokes
of any type (5, 6). Although the incidence of AKI has increased
in the past decades, short-term mortality has declined because
of advances in recognition and treatment, including the use of
short term dialysis (7). Despite recovery of an initial event of
AKI, patients remain at risk for the development of chronic
kidney disease, cardiovascular events, and reduced long term
survival (8).
For patients with aSAH, previous studies have shown that
AKI is associated with increased short-term mortality (9–
12); however, no study has evaluated the effects of AKI on
outcomes beyond 6 months. The potential impact of AKI
on long-term survival in patients with aSAH is important
to assess for two reasons. First, there are no systematic
efforts in place to monitor renal function long term after
recovery from AKI (13, 14). Second, if AKI in the context
aSAH leads to increased later mortality, methods to reduce
subsequent renal toxicity (e.g., dehydration, careful use of both
iodinated, and MRI compatible contrast agents) would become
increasingly important.
This study aimed to examine the association between AKI
and long-term mortality in 12-months survivors with aSAH
in a large, single-center cohort of patients, with death records
extracted from a government-run registry. We also examined
the association between AKI and in-hospital complications.
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Our study was approved by the Ethics Committee of
West China Hospital (No. 20191133). In this retrospective,
single-center, cohort study, we compared long-term mortality
in 12-months aSAH survivors who either had or did not
have an episode of AKI during their hospital admission.
Data were collected from the electronic health records of
all patients admitted to the West China Hospital, Sichuan
University between December 2013 and June 2019. Subsequent
survival records were extracted from the Household Registration
Administration System, a government-run provincial database
in China which mandates updated mortality records on all
patients, even those who have no follow-up after discharge
from the hospital. The institutional review board of the ethics
committee of West China Hospital approved the study and
granted a waiver of informed consent. The study complied
with the STROBE criteria (Strengthening the Reporting of
Observational Studies in Epidemiology) (15).

Patient selection
All patients who were alive ≥12 months after the index
aSAH were included. aSAH was confirmed by preoperative
neuroimaging, cerebrospinal fluid analysis, or the patient’s
neurosurgeon during a surgical procedure to clip the aneurysm.
Participants were excluded if their subarachnoid bleed was
related to trauma, rupture of an arteriovenous malformations,
detection of a fusiform aneurysm, or had a previous aneurysm
treated before the index hospitalization. We also excluded
patients whose serum creatinine was not obtained within
24 h of their admission and patients with a history of
chronic kidney disease. We also excluded patients whose
household registration was not in Sichuan province or whose
personal identification number was not found in the electronic
medical record system, because that number is the only way
to study survival by searching the Household Registration
Administration System database.
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Deﬁnition of AKI

with data presented as adjusted hazard ratios (HR) and 95%
CI. All baseline variables with a value of p < 0.20 in univariate
analyses were included into multivariate analyses. We selected
the explanatory variables based on covariates examined in
prior studies and clinical expertise. We assessed the degree of
multicollinearity among the various variables using variance
inflation factor (VIF) analysis with a VIF threshold of 10.
We also performed a propensity score-matched analysis (4,
17). A propensity score was calculated based on the probability
of a patient having AKI. This score was calculated using
a logistic regression model with AKI as the outcome and
patient factors as determinants (age, sex, hypertension, diabetes
mellitus, smoking, alcohol use, Hunt and Hess grade, Fisher
grade, aneurysm location, aneurysm size, external ventricular
drain, and aneurysm treatment). The matching variables were
based on covariates examined in prior studies and clinical
expertise (10, 12, 18–20). This predicted probability was used as
a score for one to four matching cases with the nearest neighbor
matching with calipers of 0.20 standard deviation; a difference
more than 0.10 is considered meaningful. Overall survival was
compared between matched groups.
We conducted a sensitivity analysis to assess the association
between AKI and in-hospital complications, including AKI,
hydrocephalus, delayed cerebral ischemia, rebleeding, seizures,
and hospital infection.
We used the E-value to measure the robustness of
the association between AKI and long-term mortality for
unmeasured or unadjusted confounding (21). E-values
were computed with an online E-value calculator (https://
www.evalue-calculator.com/)
(22).
Model
assessment
was conducted using C statistic and Hosmer-Lemeshow
goodness-of-fit statistics.

We adopted the definition of AKI as defined by The Kidney
Disease Improving Global Outcomes (KDIGO) guidelines (16).
Namely, the change in serum creatinine during hospitalization
was compared with baseline serum creatinine: stage 1, >0.3
mg/dL (>26.4 µmol/L) or >1.5- to 2-fold increase; stage 2: >2to 3-fold increase; and stage 3: >4.0 mg/dL (>353.6 µmol/L),
>3-fold increase in serum creatinine, or a need for renal
replacement therapy. Urinary output was not considered for the
definition of the AKI in this study due to insufficient data. At
the time of discharge renal failure recovery was evaluated by
comparing the discharge serum creatinine to the baseline serum
creatinine. In this study, renal recovery is defined as serum
creatinine returning to 1.5-fold of baseline serum creatinine
without the need for renal replacement therapy. If the discharge
creatinine was >1.5-fold of baseline serum creatinine, persistent
renal dysfunction was confirmed.

Outcome measures
The primary outcome was long-term mortality, defined
as all-cause mortality at the longest follow-up after 1 year.
Secondary outcomes were in-hospital complications, including
hydrocephalus, delayed cerebral ischemia, rebleeding, seizures,
pneumonia, intracranial infection, urinary tract infection, and
bloodstream infection.
Death records were extracted from the databases of the
Household Registration Administration System with a censoring
date of April 20, 2021. In China, every resident has a unique
identification number. When a patient dies, the law requires that
a death certificate must be entered in the household registration
in the bureau of public security within 30 days. As the death
certificate database is accurate and complete, the rate of loss
to follow-up of this study was negligible, and event time or
censoring time is known exactly.

Results
The definition of the study population is shown in
Supplementary Figure 1. There were 2,592 patients living 12
months after aSAH. Records confirmed that 238 (9.2%) had an
episode of AKI during hospitalization: 197 (7.6%) had AKI stage
1, 27 (1.1%) had stage 2, and 14 (0.6%) had stage 3 (Table 1). VIF
values in this study were each substantially lower than threshold.
Older age, male sex, history of diabetes mellitus, history of
hypertension, and severe hemorrhage (including higher Hunt
and Hess grade and higher Fisher grade) were associated with
an increased risk of AKI. In addition, patients with AKI were
more likely to have complications (Supplementary Table 1). AKI
resolved in 199 (83.6%) patients, however, 39 (16.4%) had
persistent renal dysfunction at the time of hospital discharge.
In the 2,592 patients living at least 12 months after
their aSAH, the mean observation period was 4.3 years
(range 1.0–7.3 years). During the total follow-up interval
278 (10.7%) patients died. Kaplan-Meier survival analysis

Statistical analysis
All analyses were done with R version 4.0.3 (Foundation
for Statistical Computing) and SPSS version 26 (SPSS Inc).
Continuous variables were reported as means (with standard
deviation), and categorical variables were reported as counts
(frequencies). A 2-sided P < 0.05 was considered significant. We
used multiple imputation to impute all missing values, the mean
was imputed.
We examined unadjusted overall survival using KaplanMeier analyses and using the log-rank test to determine
significant differences between groups. Multivariable survival
analyses were done using Cox proportional hazards models to
determine the independent effect of AKI on overall survival,
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TABLE 1 Baseline characteristics of the patients.

Characteristics

No AKI
(n = 2,354)

AKI Stage 1
(n = 197)

AKI Stage 2
(n = 27)

AKI Stage 3
(n = 14)

p*

py

Demographics
Age, year
Female

55.2 (11.8)

56.7 (11.4)

60.5 (13.0)

58.1 (12.6)

0.01

0.43

1,565 (66.5%)

109 (55.3%)

16 (59.3%)

8 (57.1%)

0.001

0.01

1,788 (76.0%)

140 (71.1%)

19 (70.4%)

12 (85.7%)

0.22

0.53

444 (18.9%)

48 (24.4%)

6 (22.2%)

2 (14.3%)

0.50

Smoking
Never
Current
Ever

122 (5.2%)

9 (4.6%)

2 (7.4%)

0 (0%)

Alcohol abuse

444 (18.9%)

35 (17.8%)

8 (29.6%)

2 (14.3%)

1.00

Hypertension

581 (24.7%)

60 (30.5%)

6 (22.2%)

7 (50.0%)

<0.05

0.05

Diabetes

121 (5.1%)

18 (9.1%)

2 (7.4%)

1 (7.1%)

0.03

0.12

2,152 (91.4%)

153 (77.7%)

20 (74.1%)

12 (85.7%)

0.19

0.43

0.87

0.84

<0.001

<0.001

0.01

0.12

Medical history

Anterior circulation aneurysm
Size of aneurysm, cm

0.68 (0.51)

0.68(0.55)

0.59 (0.21)

0.71 (0.25)

Miss

539 (22.9%)

29 (14.7%)

5 (18.5%)

4 (28.6%)

Hunt and Hess grade
I

246 (10.5%)

11 (5.6%)

3 (11.1%)

0 (0%)

II

1,338 (56.8%)

75 (38.1%)

9 (33.3%)

3 (21.4%)

III

574 (24.4%)

68 (34.5%)

9 (33.3%)

3 (21.4%)

IV

178 (7.6%)

38 (19.3%)

6 (22.2%)

7 (50.0%)

V

18 (0.8%)

5 (2.5%)

0 (0%)

1 (7.1%)

Fisher grade
I

119 (5.1%)

6 (3.0%)

0 (0%)

0 (0%)

II

410 (17.4%)

27 (13.7%)

2 (7.4%)

1 (7.1%)

III

309 (13.1%)

26 (13.2%)

3 (11.1%)

1 (7.1%)

IV

1,000 (42.5%)

104 (52.8%)

17 (63.0%)

7 (50.0%)

516 (21.9%)

34 (17.3%)

5 (18.5%)

5 (35.7%)

30 (1.3%)

12 (6.1%)

3 (11.1%)

1 (7.1%)

<0.001

<0.001

1,550 (65.8%)

149 (75.6%)

15 (55.6%)

9 (64.3%)

0.02

0.01

Miss
External ventricular drain
Treatment aneurysms
Clip
Coil

315 (13.4%)

15 (7.6%)

2 (7.4%)

0 (0%)

No treatment

489 (20.8%)

33 (16.8%)

10 (37.0%)

5 (35.7%)

AKI, acute kidney injury.
* Comparing patients without AKI to all patients with AKI.
y Comparing patients within the three subgroups of AKI patients.

demonstrated a significantly reduced survival in patients
with AKI compared with no AKI (Supplementary Figure 2).
Univariate Cox regression analysis found that AKI compared
with no AKI was associated with higher risk of death (HR
2.95, 95% CI 2.21–3.94). Multivariate Cox regression analysis
also identified AKI (adjusted HR 2.13, 95% CI 1.57–2.88), age,
aneurysms size, Hunt and Hess grade, external ventricular drain,
and aneurysm treatment as independent predictors of long-term
mortality (Supplementary Table 2). The E-value of adjusted HR
for long-term mortality in multivariate Cox regression analysis
was 3.68, with a confidence interval of 2.52, suggesting that
unmeasured confounders were unlikely to explain the entirety of

Frontiers in Neurology

the effect. The Hosmer-Lemeshow test demonstrated P = 0.42,
and the C statistic was 0.78, indicating the discriminatory ability
of this model was good, without departure from a good fit.
We also adjusted confounders using propensity score
matching. After matching, these groups were balanced in
all patients’ characteristics (Supplementary Table 3), and the
association between AKI and mortality was unchanged (adjusted
HR 1.77, 95% CI 1.27–2.48; Supplementary Figure 3).
Kaplan-Meier survival curves illustrated that patients
stratified by AKI severity still had significantly worse long-term
survival over the follow-up period (Figure 1). The severity of
AKI was associated with a progressively increased HR for death
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FIGURE 1

Long-term survival of patients who were alive 12 months stratiﬁed by acute kidney injury severity.

TABLE 2 Cox proportional hazards model for long-term mortality, stratiﬁed by acute kidney injury severity.

Acute kidney injury severity

Events, n/N (%)

Unadjusted
HR (95% CI)

Multivariable adjustment
p

HR (95% CI)

p

No acute kidney injury

220/2354 (9.3)

[reference]

Stage 1

45/197 (22.8)

2.73 (1.98–3.76)

<0.001

2.08 (1.49–2.89)

Stage 2

8/27(29.6)

3.68 (1.82–7.46)

<0.001

2.15 (1.05–4.43)

0.04

Stage 3

5/14(35.7)

5.03 (2.07–12.22)

<0.001

2.66 (1.08–6.53)

0.03

<0.001

Discussion

(Table 2). Compared with no AKI in multivariate Cox regression
analysis, patients with stage 1 AKI had an adjusted HR of 2.08
(95% CI 1.49–2.89); patients with stage 2 AKI had an adjusted
HR of 2.15 (95% CI 1.05–4.43), and patients with stage 3 AKI
had an adjusted HR of 2.66 (95% CI 1.08–6.53).
Patients with renal recovery at the time of hospital discharge
had a significantly higher risk of dying later compared to patients
without AKI (adjusted HR 1.96; 95% CI 1.40–2.74; Figure 2 and
Supplementary Table 4). The survival rate for patients with AKI
renal recovery at discharge was higher than patients without
renal recovery (adjusted HR 1.95, 95% CI 1.04–3.67).
Effect modification is present with aneurysm location (P for
interaction = 0.02) and aneurysm treatment (P for interaction
<0.001; Supplementary Figure 4). There was no significant
effect modification of AKI and long-term mortality on the
other variables.
Sensitivity analysis remains a significant effect on AKI and
long-term mortality (OR 2.01, 95% CI 1.35–2.96, P < 0.001;
Supplementary Table 5).

Frontiers in Neurology

[reference]

In this large, single-center retrospective cohort study of
patients who survived 12 months after aSAH, we found that AKI
during hospitalization was associated with reduced long-term
survival. As the severity of the AKI event increased, the risk of
death progressively increased. Even patients who had recovered
from AKI at the time of hospital discharge still had increased
long-term mortality compared with patients without AKI.

Comparison with other studies
To our knowledge, the association between AKI and longterm outcomes in patients with aSAH has not been studied
previously; however, we are aware of several studies assessing
short-term outcomes, which suggested increased mortality
among patients with AKI (Supplementary Table 6). In a study
of 787 patients with aSAH, patients with risk for renal failure
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FIGURE 2

Long-term survival of patients who were alive 12 months with and without an acute kidney injury, stratiﬁed by renal recovery.

Strengths and limitations

as defined by RIFLE(Risk, Injury, Failure, Loss, and End stage)
criteria, had worse 3-month outcomes and higher mortality
rates compared to those not at risk (P < 0.0001) (12). In a
claims database analysis of hospitalizations for aSAH in the
United States, the incidence of acute renal failure (based on
validated ICD-9-CM codes) in patients hospitalized for aSAH
was 4.0%, and patients with acute renal failure had an increased
likelihood of in-hospital death (OR, 2.14; 95% CI, 2.03–2.26)
(10). In a recent study of 243 patients with SAH, AKI (defined
by the AKIN [acute kidney injury network] criteria) was more
frequent in ICU non-survivors but was not an independent
predictor of ICU mortality in multivariable analysis (9).

This study has several strengths. The large cohort size allows
adjustment for potential confounders and results in an enhanced
dose-response relationship. We determined long-term mortality
based on the household registration system that is considered
accurate, up to date, and without lost follow-up.
This study has some limitations. First, potential weaknesses
include the retrospective, observational analysis making causal
inference difficult and subject to bias from unmeasured factors.
Our hospital records could not systematically capture data on
daily urine output values, which may lead to underestimation
of the incidence of AKI. Second, this study did not contain
information on either co-morbid diseases during the followup period or actual cause of death. Future studies should
examine the association with cause-specific mortality. Third, our
study is a single-center study. Whether our findings could be
applied to other hospitals needed more research to confirm.
Fourth, we cannot collect all confounders of the association
between AKI and mortality, and thus other factors may affect the
results. However, the E-value of the association suggested that
unmeasured confounders were unlikely to explain the entirety
of the effect.

Mechanism
The underlying mechanisms of the relation between AKI
and long-term mortality are still under investigation (8). AKI
can be a reflection of the general insult of critical illness and
may be a marker of systemic illness. Moreover, AKI can exhibit
important effects on outcomes that extend well after hospital
discharge. Several studies have identified that an episode of AKI
may herald eventual long-term renal disease, such as recurrent
AKI and development of chronic kidney disease (23, 24).
Chronic kidney disease has been reported as 17.76 cases per 100
person-years following AKI (23). AKI also is associated with
poorer long-term cardiovascular health. A systematic review
of 25 studies involving 254,408 patients found that AKI is
associated with a 58% increased risk of eventual heart failure and
a 40% increased risk of acute myocardial infarction (25). Patients
with chronic kidney disease and cardiovascular disease after AKI
have higher mortality rates (8, 26).

Frontiers in Neurology

Implication
This study found that AKI during hospitalization for aSAH
was associated with long-term mortality, even for patients with
renal recovery at the time of discharge (13, 27). The current
KDIGO guidelines recommend patients should be followed by
a nephrologist for more than 3 months after an AKI episode
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in order to estimate kidney recovery and/or progression to
chronic kidney disease (28). The present study indicates that
patients should have long-term post-discharge monitoring of
renal function, regardless of renal recovery at the time of
discharge. AKI may result in ongoing progressive renal damage
beyond the acute episode, despite marginal increases in serum
creatinine. This is an important insight for all physicians who
care for patients with aSAH, and future studies will need to
determine the optimal timing for follow-up of renal function
and develop biomarkers of the transition from AKI to chronic
kidney disease for patients with AKI during hospital.
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